Quick Answer
ADC Therapeutics SA reported Stockholders Equity of -$185.83 million for the year ending 2025.
- ADC Therapeutics SA showed an increase of +8.3% in Stockholders Equity from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $28.42 million | Q2 2023: -$19.70 million | Q3 2023: -$64.25 million | Q1 2024: -$194.45 million | Q2 2024: -$131.67 million | Q3 2024: -$171.95 million | Q1 2025: -$238.22 million | Q2 2025: -$199.18 million | Q3 2025: -$238.18 million.
- Over the full 5 years of available data (2021 to 2025), ADC Therapeutics SA's Stockholders Equity has declined by 220.7%.
- Historical annual values: Fiscal year 2025: -$185.83 million | Fiscal year 2024: -$202.64 million | Fiscal year 2023: -$148.25 million | Fiscal year 2022: $79.45 million | Fiscal year 2021: $154.03 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: